Trends in cervical cancer incidence in sub-Saharan Africa.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
14
10
2019
accepted:
18
03
2020
revised:
17
02
2020
pubmed:
28
4
2020
medline:
20
2
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Cervical cancer is the second most common cancer and the leading cause of cancer death in women in sub-Saharan Africa (SSA). Trends in the incidence of cervical cancer are examined for a period of 10-25 years in 10 population-based cancer registries across eight SSA countries (Gambia, Kenya, Malawi, Mauritius, Seychelles, South Africa, Uganda and Zimbabwe). A total of 21,990 cases of cervical cancer were included in the analyses. Incidence rates had increased in all registries for some or all of the periods studied, except for Mauritius with a constant annual 2.5% decline. Eastern Cape and Blantyre (Malawi) registries showed significant increases over time, with the most rapid being in Blantyre (7.9% annually). In Kampala (Uganda), a significant increase was noted (2.2%) until 2006, followed by a non-significant decline. In Eldoret, a decrease (1998-2002) was followed by a significant increase (9.5%) from 2002 to 2016. Overall, cervical cancer incidence has been increasing in SSA. The current high-level advocacy to reduce the burden of cervical cancer in SSA needs to be translated into support for prevention (vaccination against human papillomavirus and population-wide screening), with careful monitoring of results through population-based registries.
Sections du résumé
BACKGROUND
Cervical cancer is the second most common cancer and the leading cause of cancer death in women in sub-Saharan Africa (SSA).
METHODS
Trends in the incidence of cervical cancer are examined for a period of 10-25 years in 10 population-based cancer registries across eight SSA countries (Gambia, Kenya, Malawi, Mauritius, Seychelles, South Africa, Uganda and Zimbabwe). A total of 21,990 cases of cervical cancer were included in the analyses.
RESULTS
Incidence rates had increased in all registries for some or all of the periods studied, except for Mauritius with a constant annual 2.5% decline. Eastern Cape and Blantyre (Malawi) registries showed significant increases over time, with the most rapid being in Blantyre (7.9% annually). In Kampala (Uganda), a significant increase was noted (2.2%) until 2006, followed by a non-significant decline. In Eldoret, a decrease (1998-2002) was followed by a significant increase (9.5%) from 2002 to 2016.
CONCLUSION
Overall, cervical cancer incidence has been increasing in SSA. The current high-level advocacy to reduce the burden of cervical cancer in SSA needs to be translated into support for prevention (vaccination against human papillomavirus and population-wide screening), with careful monitoring of results through population-based registries.
Identifiants
pubmed: 32336751
doi: 10.1038/s41416-020-0831-9
pii: 10.1038/s41416-020-0831-9
pmc: PMC7341858
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
148-154Références
Int J Cancer. 2018 Nov 1;143(9):2238-2249
pubmed: 29786136
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
Infect Agent Cancer. 2017 Nov 29;12:61
pubmed: 29213299
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
BMJ Open. 2016 Jan 21;6(1):e007690
pubmed: 26801459
Int J Cancer. 2014 Jul 15;135(2):432-9
pubmed: 24615279
Cancer Epidemiol. 2018 Apr;53:81-92
pubmed: 29414636
Br J Cancer. 2014 Aug 26;111(5):965-9
pubmed: 24992581
Trop Med Int Health. 2009 Oct;14(10):1287-302
pubmed: 19772550
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):537-47
pubmed: 7827583
Pac AIDS Alert Bull. 1999;(18):15-6
pubmed: 12349391
Reprod Health Matters. 2008 Nov;16(32):104-12
pubmed: 19027628
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
BMJ Open. 2016 Jan 11;6(1):e008533
pubmed: 26754174
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Int J Cancer. 2015 Mar 1;136(5):E470-4
pubmed: 25236502
Cancer Epidemiol. 2012 Oct;36(5):e271-8
pubmed: 22621842
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Int J Cancer. 2015 Nov 1;137(9):2053-9
pubmed: 26139540
Malawi Med J. 2017 Jun;29(2):124-129
pubmed: 28955419
Eur J Cancer. 2009 Mar;45(5):747-55
pubmed: 19117750
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2013 Aug 1;133(3):721-9
pubmed: 23364833
Public Health Monogr. 1959;56:1-207
pubmed: 13634308